Our research programme currently includes randomised trials in cardiovascular disease, diabetes mellitus, chronic kidney disease and cancer.
We specialise in designing and coordinating very large, cost-efficient, trials, using innovative methods developed in conjunction with our in-house computing and laboratory teams. Our unique approach to streamlined trial design has allowed us to conduct some of the largest international randomised trials.
In cardiovascular disease the 20,000 patient Heart Protection Study (HPS) and the 12,000 patient SEARCH trial, showed that lowering LDL cholesterol with statin therapy is beneficial among patients at high risk of cardiovascular disease. It had been thought that niacin/laropiprant might be beneficial because it raises HDL cholesterol but the 25,000 patient THRIVE trial showed it to be ineffective and associated with previously unrecognised adverse effects.
In chronic kidney disease, we coordinated the 9,500 patient Study of Heart and Renal Protection (SHARP), the largest ever trial in this condition, which showed that lowering LDL cholesterol is beneficial and not associated with adverse effects.
In cancer, our 13,000 patient Adjuvant Tamoxifen: Longer against Shorter (ATLAS) trial showed that ten years of adjuvant tamoxifen was superior to five years of treatment after a diagnosis of oestrogen-positive breast cancer.